NICE is the public health body guiding UK treatments and care policies, now thrust into headlines as decision-making and policy impact face scrutiny.
Nice has issued a draft guideline for PMOS that mandates annual checks, earlier diagnosis, and monitoring of long-term risks. It renames the condition from PCOS to PMOS to reflect broader health impacts. It also rules out laser hair removal as a cost-ineffective treatment, instead urging contraception-based management and IVF options where appropriate.
A look at why more young adults are living with their parents in the UK, reflecting housing pressures, finances, and shifts in independence. The trend is reshaping family dynamics and property markets.
The NHS in England and Wales has approved teplizumab, the first drug that can delay onset of type 1 diabetes. The immunotherapy offers up to three extra years before symptoms require lifelong insulin, with rollout backed by NICE and a commercial deal with Sanofi.